DJIA 17,031.14 43.63 0.26%
NASDAQ 4,518.90 -48.70 -1.07%
S&P 500 1,984.13 -1.41 -0.07%
market minute promo

Nektar Therapeutics (NASDAQ: NKTR)

company name or ticker

NKTR Makes Notable Cross Below Critical Moving Average

Nektar Rises on FDA Notification - Analyst Blog

Nektar Therapeutics (NKTR) Jumps: Stock Up 10.5% - Tale of the Tape

Wider-than-Expected Loss at Nektar, Guidance Disappoints - Analyst Blog

Today's Biggest Stories in Biotech: Galectin Therapeutics Inc, Merrimack Pharmaceuticals and Nektar

Top stories in biotech and healthcare today.

Nektar Therapeutics' CEO Discusses Q4 2013 Results - Earnings Call Transcript

3 Under-the-Radar Biotech Stocks You Need to Watch in 2014

Nektar Therapeutics, Omeros, and Spectrum Pharmaceuticals all face off with regulators in key decision dates for their developmental drugs later this year

Can Nektar Therapeutics Beat Pfizer Inc.?

In addition to Remoxy, Pfizer has an in-house formulation of abuse-resistant oxycodone in late stage trials. Could an all new opioid from Nektar Therapeutics upend both programs?

Russell 2000 Rebalance May Bring Huge Buying in Key Stocks

Nektar Therapeutics (NKTR) Looks Good: Stock Up 6.8% in Session - Tale of the Tape

See More Articles...